MYLK and neoplasm: Cytoskeletal myosin II phosphorylated by MYLK increases the metastatic potential of tumor cells, and MYLK-dependent cytoskeleton rearrangement adjusts the angiogenesis of the vascular endothelial barrier, which is an inevitable step in cancer metastasis [7].